Category: Uncategorized
CuraCell TX AB (CuraCell) has announced the appointment of Dr Thomas Jaecklin and Prof Martin Forster to its Board of Directors, further strengthening the company’s leadership as it advances its mission to develop transformative cell-based therapies.
Read the full release here.
CuraCell CEO Jonas Batelson recently spoke to Jonathan Smith, a reporter for Mergermarket, about the companies plans for its next funding round to allow its TIL therapy trials to proceed.
Read the article here.
In Vivo recently published a profile on how Italian biotech AAVantgarde is advancing dual-vector AAV gene therapy for two inherited retinal diseases (Stargardt and Usher syndrome type 1B) using a staged de-risking strategy that leverages data from one programme to underpin the next.
Read the full story here.
Pink Sheet recently featured an interview with Cereno Scientific's CEO, Sten Sorensen, on the benefits of leveraging existing safety data from its broader HDAC platform to streamline the development of its pulmonary hypertension drug, CS014. As the journalst, Aakash Babu states, for cash‑strapped biotechs, this model offers a blueprint for capital‑efficient development.
Read the article here.
A new collaboration between BetterSeeds and Caszyme aims to bypass one of the most persistent constraints in plant gene editing: tissue culture. By combining ultra‑compact Cas12l nucleases with engineered plant viral vectors, the partners say they can deliver precise gene edits directly into crops, cutting time, cost and genotype dependency while making CRISPR more accessible to seed companies.
Read the full article here.
One-carbon CEO Ana Slipicevic sat down with Anette Briendl of BioWorld at the recent BIO Europe Spring conference to discuss the company's first-in-class inhibitor of MTHFD1/2.
Read the subsequent article here: https://www.bioworld.com/articles/730118-one-carbon-has-new-approach-to-starving-tumors-of-nucleotides?v=preview
Based on an interview done at BIO-Europe, Dicot Pharma CEO Elin Trampe talked to Pharma Vanguard about how erectile dysfunction is no longer important within the realms of just sexual health, but has been established as an indicator within the field of longevity.
Read the full interview here.
As part of its Inventive Step series, MedNous published an article by HaemaLogiX co-founder Rosanne Dunn in its March issue.
The article detailed how, for decades, a therapy for multiple myeloma that selects for the malignant cell and spares its benign counterpart has only been a theoretical idea. However, research from Dunn and her team at HaemaLogix has finally made this approach a reality.
Reach more about the approach here.
CuraCell TX AB announced that the first patient has been successfully included into its ongoing Phase I/IIa clinical trial evaluating the company’s novel autologous Tumor-Infiltrating Lymphocyte (TIL) therapy, CC-38, for patients with metastatic colorectal and metastatic prostate cancer.
Read the full announcement here.
HaemaLogiX is highlighted in Drug Target Review for work identifying KMA and LMA antigens as promising therapeutic targets in plasma cell dyscrasias, a group of disorders that includes multiple myeloma. The piece outlines why these antigens are considered high‑value: they show selective expression on malignant plasma cells and present opportunities for targeted modalities such as antibody–drug conjugates and engineered cell therapies.
Targeting KMA and LMA could improve tumour specificity and reduce off‑target toxicity compared with broader approaches, potentially enabling deeper remissions for patients with relapsed or refractory disease. The article highlights our client’s role in advancing antigen validation and preclinical development, including biomarker characterisation and early translational studies that support clinical candidate selection.
Read the full story here.